2026 Summer Intern – Operational Excellence & Compliance at Acadia Pharmaceuticals

Parsippany, New Jersey, United States

Acadia Pharmaceuticals Logo
Not SpecifiedCompensation
InternshipExperience Level
InternshipJob Type
UnknownVisa
Biopharmaceutical, ManufacturingIndustries

Requirements

  • Engineering undergraduate student (preference Industrial, Mechanical, Chemical, Biomedical) or Computer Science
  • Preferred experience with AI tools, Microsoft 365, and TrackWise
  • Must be available to work onsite at the Parsippany, NJ office 5 days per week
  • Ability to complete the entire 10-week program (from May 26, 2026 to July 31, 2026) and commit to 37.5 hours per week
  • Cumulative 3.0 GPA or above; college transcript required (must mail official transcript by application deadline to specified address)
  • Currently enrolled in an accredited U.S. based college or university
  • Enrolled in either an undergraduate (Bachelor’s), graduate, MBA, JD, PharmD, or PhD program
  • Legally authorized to work in the U.S. without a need for sponsorship/CPT/OPT now or in the future
  • At least 18 years of age prior to the scheduled start date
  • Must be available to complete virtual interviews with HR and hiring manager
  • Must successfully pass a drug screen and background check prior to start date
  • Must complete a final presentation at the end of the 10-week program (mandatory)

Responsibilities

  • Learn and study the topic of AI tools and AI agents to apply to the deviations management process
  • Develop/build database of historical deviations in TrackWise
  • Develop AI agents to apply to the deviations management process
  • Support implementation of improvements

Skills

AI tools
AI agents
TrackWise
Microsoft 365
deviations management
database development

Acadia Pharmaceuticals

Develops therapies for neurological disorders

About Acadia Pharmaceuticals

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, seeking approval from regulatory bodies like the FDA before bringing them to market. Acadia differentiates itself by targeting areas with significant unmet medical needs, ensuring that their products address critical health challenges. Their goal is to improve the quality of life for patients suffering from these disorders while also promoting diversity, equity, and inclusion within their operations.

Dallas, TexasHeadquarters
1993Year Founded
$813.4MTotal Funding
ACQUISITIONCompany Stage
Biotechnology, HealthcareIndustries
501-1,000Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Paid Vacation
Paid Holidays
Paid Sick Leave
Paid Parental Leave
Tuition Reimbursement

Risks

Increased competition in CNS drug market may impact Acadia's market share.
Potential clinical trial delays could affect drug approval timelines.
Dependence on partnerships poses risks if collaborations face challenges or dissolve.

Differentiation

Acadia focuses on CNS disorders with unmet medical needs, like Parkinson's and Rett syndrome.
The company has a strong R&D foundation, developing innovative small molecule drugs.
Acadia's strategic partnerships enhance its research capabilities and market reach.

Upsides

Acadia's collaboration with Saniona expands its portfolio with SAN711 for neurological disorders.
Health Canada's approval of Daybue boosts Acadia's presence in the Canadian market.
The rise of personalized medicine aligns with Acadia's targeted therapy approach.

Land your dream remote job 3x faster with AI